中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 2
Feb.  2009
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2009  >  25(2): 122-124

肝细胞性肝癌患者介入治疗前后血清蛋白质组的变化

  • Published Date: 2009-02-20
    Abstract
  • Objective To detect the serum proteomic patters in hepatocellular carcinoma (HCC) patients treated by interpose chemotherapy by using SELDI-TOF-MS (surface-enhanced laser desorption-ionization time-of-flight mass spectrometry) protein chip array technology, screen drug targets, evaluate its clinical significance.Methods 50 cases of the patients with hepatocellular carcinoma without receiving any therapy, 50 cases of the patients with hepatocellular carcinoma receiving the interpose chemotherapy were tested by weak cationic exchanger protein chip and surface-enhanced laser desorption-ionization time-of-flight mass spectrometry.The diagnostic models were developed and validated by BioMarker Wizard.Results At the different M/Z value range, three proteins were obviously different in the group of the patients with hepatocellular carcinoma without receiving any therapy, the patients with hepatocellular carcinoma receiving the interpose chemotherapy.Through searching databases we have got three probably significant proteins related with them.Conclusions Detection of serum proteomic patters for hepatocellular carcinoma treated by interventional therapy using SELDI-TOF-MS protein chip array is quick and effective.These differential proteins could be drug targets of hepatocellular carcinoma before and after the interpose chemotherapy in the serum.

     

    • FullText(HTML)
    • References(24)
  • [1]Schwegler EE, Cazares L, Steel LF, et al.SELDI-TOF MS profi-ling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma[J].Hepatology, 2005, 41∶634-642.
    [1]Schwegler EE, Cazares L, Steel LF, et al.SELDI-TOF MS profi-ling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma[J].Hepatology, 2005, 41∶634-642.
    [2]Paradis V, Degos F, Dargere D, et al.Identification of a newmarker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver disease[J].Hepatology, 2005, 41∶40-47.
    [2]Paradis V, Degos F, Dargere D, et al.Identification of a newmarker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver disease[J].Hepatology, 2005, 41∶40-47.
    [3]Roelofsen H, Balgobind R, Vonk RJ.Proteomic analyzes of copper metabolism in an in vitro model of Wilson disease using surface en-hanced laser desorption/ionization-time of flight-mass spectrome-try[J].J Cell Biochem, 2004, 93∶732-740.
    [3]Roelofsen H, Balgobind R, Vonk RJ.Proteomic analyzes of copper metabolism in an in vitro model of Wilson disease using surface en-hanced laser desorption/ionization-time of flight-mass spectrome-try[J].J Cell Biochem, 2004, 93∶732-740.
    [4]汤钊猷.现代肿瘤学[M].上海:上海医科大学出版社, 1993∶561.
    [4]汤钊猷.现代肿瘤学[M].上海:上海医科大学出版社, 1993∶561.
    [5]Parasole R, Izzo F, Perrone F, et al.Prognostic value of serum bio-logical markers in patients with hepatocellular carcinoma[J].Clin Cancer Res, 2001, 7∶3504-3509.
    [5]Parasole R, Izzo F, Perrone F, et al.Prognostic value of serum bio-logical markers in patients with hepatocellular carcinoma[J].Clin Cancer Res, 2001, 7∶3504-3509.
    [6]李悦国, 张维铭.蛋白质组学在肝癌及其相关疾病研究中的应用[J].中国肿瘤临床, 2005, 32∶957-960.
    [6]李悦国, 张维铭.蛋白质组学在肝癌及其相关疾病研究中的应用[J].中国肿瘤临床, 2005, 32∶957-960.
    [7]Wu W, Hu W, Kavanagh JJ.Proteomics in cancer research[J].Int J Gynecol Cancer, 2002, 12∶409-423.
    [7]Wu W, Hu W, Kavanagh JJ.Proteomics in cancer research[J].Int J Gynecol Cancer, 2002, 12∶409-423.
    [8]Lueking A, Cahill DJ, Mullner S.Protein biochips:A newand ver-satile platform technology for molecular medicine[J].Drug Discov Today, 2005, 10∶789-794.
    [8]Lueking A, Cahill DJ, Mullner S.Protein biochips:A newand ver-satile platform technology for molecular medicine[J].Drug Discov Today, 2005, 10∶789-794.
    [9]Figeys D, Pinto D.Proteomics on a chip:promising developments[J].Electrophoresis, 2001, 22∶208-216.
    [9]Figeys D, Pinto D.Proteomics on a chip:promising developments[J].Electrophoresis, 2001, 22∶208-216.
    [10]Issaq HJ, Veenstra TD, Conrads TP, et al.The SELDI-TOF MS ap-proach to proteomics:protein profiling and biomarker identification[J].Biochem Biophys Res Commun, 2002, 292∶587-592.
    [10]Issaq HJ, Veenstra TD, Conrads TP, et al.The SELDI-TOF MS ap-proach to proteomics:protein profiling and biomarker identification[J].Biochem Biophys Res Commun, 2002, 292∶587-592.
    [11]Petricoin EF, Ardekani AM, Hitt BA, et al.Use of proteomic pat-terns in serum to identify ovarian cancer[J].Lancet, 2002, 359∶572.
    [11]Petricoin EF, Ardekani AM, Hitt BA, et al.Use of proteomic pat-terns in serum to identify ovarian cancer[J].Lancet, 2002, 359∶572.
    [12]Adam BL, Qu Y, Davis JW, et al.Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from algorithm distinguishes prostate cancer from benign pros-tate hyperplasia and healthy men[J].Cancer Res, 2002, 62∶3609.
    [12]Adam BL, Qu Y, Davis JW, et al.Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from algorithm distinguishes prostate cancer from benign pros-tate hyperplasia and healthy men[J].Cancer Res, 2002, 62∶3609.
    • Relative Articles

  • Relative Articles

    [1]Mingxiu DUAN, Xinli CHEN, Weiyu CHANG, Yuan YANG, Shiqi YANG, Hui WU. Advances in the multi-omics research on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(6): 1240-1247. doi: 10.12449/JCH240626
    [2]Yi CUI, Fengjie QIAO, Jiahao QIU, Yufei LIU, Zhujun GAO, Zhi SHANG, Yueqiu GAO. Effect of ganoderic acid A on a mouse model of concanavalin A-induced acute immune liver injury and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(12): 2415-2423. doi: 10.12449/JCH241211
    [3]Kai CHANG, Yanyan WANG, Zhongyong JIANG, Wei SUN, Chenxia LIU, Wanlin NA, Hongxuan XU, Jing XIE, Yuan LIU, Min CHEN. Proteomic analysis and validation of DNA repair regulation in the process of hepatocellular carcinoma recurrence[J]. Journal of Clinical Hepatology, 2024, 40(2): 319-326. doi: 10.12449/JCH240216
    [4]Yan JIAO, Ying ZHANG, Honglin SHI, Wang LU, Dexi CHEN, Yu CHEN, Hongbo SHI. A bioinformatics analysis of differentially expressed proteins in plasma exosome of acute-on-chronic liver failure patients with different prognoses[J]. Journal of Clinical Hepatology, 2021, 37(4): 834-840. doi: 10.3969/j.issn.1001-5256.2021.04.022
    [5]Wu Han, Li ZhenLi, Xing Hao, Wang MingDa, Wu MengChao, Yang Tian. Research advances in the structure and function of osteopontin and its effect in diagnosis and treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(9): 1999-2003. doi: 10.3969/j.issn.1001-5256.2018.09.036
    [6]Xiong JingPing, Peng YuanYuan, Zhang YueXin. Screening for differentially expressed proteins in patients with liver cirrhosis complicated by portal vein thrombosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 112-117. doi: 10.3969/j.issn.1001-5256.2018.01.023
    [8]Yang ZhenYu, Du XiLin, Yang Tao, Tan Kai, He XiaoJun, Chen An. Basic research and therapeutic strategies for multinodular hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(6): 1212-1215. doi: 10.3969/j.issn.1001-5256.2016.06.046
    [9]Jia XiaoFang, Zhang XiaoNan, Wu Ao, Zhang LiJun, Yuan ZhengHong. Effect of protein acetylation on hepatitis B virus replication[J]. Journal of Clinical Hepatology, 2016, 32(8): 1497-1501. doi: 10.3969/j.issn.1001-5256.2016.08.013
    [10]Bai LiQing, Qiao JiaNi. Expression and correlation analysis of γ-glutamyl transpeptidase and alpha-fetoprotein in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(9): 1452-1454. doi: 10.3969/j.issn.1001-5256.2015.09.021
    [11]Zhang LiJun, Jia XiaoFang, Wu DaGe, Liu XiaoQian, Huang Yan, Zhang JiaoLi, Cheng NengNeng. Proteome analysis of liver nonparenchymal cells from rats with alcoholic liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1053-1059. doi: 10.3969/j.issn.1001-5256.2014.10.020
    [12]Wang XiaoYu, Luo JianPing, Cha XueQiang, Gu DongXiao. Application of proteomics and metabonomics in studies on alcoholic liver disease[J]. Journal of Clinical Hepatology, 2014, 30(2): 168-173. doi: 10.3969/j.issn.1001-5256.2014.02.018
    [13]Wang JianGang, Fei XinYing, Song Qing. Application of proteomics in study of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 958-960. doi: 10.3969/j.issn.1001-5256.2014.09.030
    [14]Zhang LiJun, Jia XiaoFang, Teng ZhenLin, Cheng NengNeng. Biomarkers of liver cancer related to hepatitis B virus selected by proteomics[J]. Journal of Clinical Hepatology, 2011, 27(5): 553-557.
    [16]Ge WenSong, Yao DingKang, Zhu Liang. Preliminary study on proteomic patterns in hepatic tissue to identify HBV related hepatic firbrosis.[J]. Journal of Clinical Hepatology, 2007, 23(5): 357-359.
    [17]Xu SanRong, Wang XueHao, Zhang Feng. Clinical study on the relationship between the apoptosis in hepatocellular carcinoma cells induced by cisplatin and the expression of Fas protein[J]. Journal of Clinical Hepatology, 2004, 20(6): 366-367.
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-042024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-0302.557.51012.5
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 7.6 %FULLTEXT: 7.6 %META: 89.5 %META: 89.5 %PDF: 2.9 %PDF: 2.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.3 %其他: 3.3 %Russian Federation: 0.4 %Russian Federation: 0.4 %上海: 0.7 %上海: 0.7 %北京: 13.8 %北京: 13.8 %南京: 1.1 %南京: 1.1 %南宁: 0.4 %南宁: 0.4 %吉林: 0.7 %吉林: 0.7 %呼和浩特: 0.4 %呼和浩特: 0.4 %哥伦布: 0.7 %哥伦布: 0.7 %张家口: 3.3 %张家口: 3.3 %成都: 0.4 %成都: 0.4 %扬州: 0.4 %扬州: 0.4 %杭州: 0.4 %杭州: 0.4 %武汉: 0.4 %武汉: 0.4 %泰州: 0.4 %泰州: 0.4 %湖州: 0.4 %湖州: 0.4 %石家庄: 0.4 %石家庄: 0.4 %芒廷维尤: 37.8 %芒廷维尤: 37.8 %苏州: 0.4 %苏州: 0.4 %莫斯科: 0.4 %莫斯科: 0.4 %衢州: 0.7 %衢州: 0.7 %西宁: 32.0 %西宁: 32.0 %长春: 1.5 %长春: 1.5 %其他Russian Federation上海北京南京南宁吉林呼和浩特哥伦布张家口成都扬州杭州武汉泰州湖州石家庄芒廷维尤苏州莫斯科衢州西宁长春

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2256) PDF downloads(831) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2482]YesterdayPV[4685]TodayIP[4]TodayPV[4]Online[53]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return